Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera, but said ...

In response to the stronger-than-expected quarter, GE HealthCare adjusted its 2025 earnings per share profit forecast to ...

Less than two years after emerging, Arena BioWorks is shuttering, citing the “adverse impact of biotech macro conditions” as ...

The news is coming thick and fast for Qiagen. As the molecular diagnostics specialist announced its third-quarter earnings, ...

Questex has acquired The Conference Forum and Versalinx Global Events, two highly respected organizers known for convening ...

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a ...

Last Thursday brought the shock announcement that Novo Nordisk had made a fresh play to buy the biotech, despite Pfizer ...

Matt Adams has become the new chief executive at BrainScope, taking over from Laurie Silver, who becomes the medical ...

The trial was halted due to inadequate efficacy, Jay Bradner, M.D., Amgen’s executive vice president of R&D, said during a Nov. 4 call with investors, after an ad hoc analysis requested by an internal ...

After a three-month delay, the FDA has now rejected an approval request based on the RWE. According to Biohaven, the FDA’s complete response letter “cited issues that can be inherent to real-world ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune ...